Algernon Health Inc. Stock Analysis AGN.CN

Algernon Health, Inc. is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them into new human trials, developing new formulations and seeking new regulatory approvals in global markets. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. The firm is focused on the provision of brain-specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. The company is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The firm also owns a 20% equity position in Seyltx, a private U.S-based drug development company advancing a chronic cough drug called Ifenprodil.